louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01518829: Procalcitonin in Hepatocellular Carcinoma
Official title: Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma
Keywords: hepatocellular carcinom
postablation syndrom
procalcitonin
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2012-01-26
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: inpatients in tropical medicine department and hepatocellular carcinoma out patient clinic ain shams university

Brief summary: the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.


Eligibility criteria: Inclusion Criteria:

1. - Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
2. - Fever more than 38C after 48 hours post intervention.

Exclusion Criteria:

1. HCC Patients who does not develop fever after intervention.
2. Proven infection elsewhere (e.g. UTI, chest infection..)

Primary outcomes:
measure: Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma
timeFrame: 6months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Tropical medicine department and hepatocellular carcinoma clinic
Study officials:
affiliation: Tropical medicine department
name: Hisham K Dabbous, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00961129: The Continuing Care Needs in Colorectal Cancer Patients in Different Stages
Official title: The Continuing Care Needs From Receiving Treatment to Survival in Colorectal Cancer Patients in Different Stages
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Colorectal Cancer
Keywords: colorectal cancer
needs
survivors
any stage
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2009-08-18
Enrollment: 269
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: recruit colon cancer inpatients and outpatients in clinics

Brief summary: The aims of this study are to:

1. explore supportive care needs in colorectal cancer patients with treatment and survivors;
2. compare the supportive care needs in different stage of colorectal cancer;
3. identify the significant factors for the supportive care needs;
4. explore the supportive care needs within one year after newly diagnosis.

Detailed description: Both large scale cross-sectional survey and a prospective 1-year longitudinal panel study design will be used in this study. The cross-sectional survey is to examine the current status of supportive care needs perceived by different stage of colorectal cancer inpatients and outpatients including survivors. The 1-year longitudinal design is to explore the change of supportive care needs perceived by patients within one year after newly diagnosed with colorectal cancer.

Eligibility criteria: Inclusion Criteria:

* Patients with colorectal cancer in any stage or survivors
* Those who are willing to participate in the research
* Aged above 18

Exclusion Criteria:

* None

Primary outcomes:
measure: supportive cancer care needs
timeFrame: For 1-year follow-up study, measurement time-points include 1, 3, 6, 9, and 12 months after diagnosis.
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University
name: shiow-ching shun, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03396029: Tailored Written Lifestyle Feedback in Colorectal Cancer Screening
Official title: A Randomized Trial of Tailored Written Lifestyle Feedback in Colorectal Cancer Screening
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lifestyle
Diet Habit
Smoking Cessation
Physical Activity
Alcohol Drinking
Body Weight
Keywords: Lifestyle intervention
Diet
Smoking cessation
Physical activity
Alcohol
Body mass index
colorectal cancer screening
sigmoidoscopy
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2018-01-10
Enrollment: 3642
Sex: ALL
Minimum age (years): 50
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This randomized controlled trial aims to investigate the effect of an individually tailored lifestyle feedback letter and a leaflet on lifestyle in the context of sigmoidoscopy screening.

Detailed description: Cancer screening may be used as a teachable moment for healthy lifestyle behaviours. This study aims to investigate the effect of minimal, but individually tailored lifestyle advice and a standard leaflet on healthy lifestyle given at a colorectal cancer screening context on one-year changes in these behaviours in a population-based sample of men and women.

Individuals invited to sigmoidoscopy screening in the piloting of Norwegian Bowel Cancer Screening are additionally invited to this lifestyle intervention study. Changes in lifestyle are measured by a brief lifestyle questionnaire administered at prescreening and after one year. The intervention to the intervention arms is given after completion of the prescreening lifestyle questionnaire.

Eligibility criteria: Inclusion Criteria:

* Invited to sigmoidoscopy screening in the Norwegian Bowel Cancer Screening Pilot Study

Exclusion Criteria:

* Excluded from sigmoidoscopy screening due to medical reasons, previous colorectal cancer diagnosis, relocating out of the screening municipalities or previous colonoscopy in the last 12 months.

Primary outcomes:
measure: A questionnaire-based lifestyle score
timeFrame: One year; from pre-screening until one year after
Secondary outcomes:
measure: Smoking status
timeFrame: One year; from pre-screening until one year after
measure: Alcohol consumption
timeFrame: One year; from pre-screening until one year after
measure: Physical activity
timeFrame: One year; from pre-screening until one year after
measure: Consumption of fruit and vegetables
timeFrame: One year; from pre-screening until one year after
measure: Body weight
timeFrame: One year; from pre-screening until one year after
Other outcomes:
Locations:
Study officials:
affiliation: Norwegian Institute of Public Health
name: Paula Berstad, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00005429: Clinical Cardiovascular Outcomes of African-Americans
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Diseases
Heart Diseases
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Sponsor class: NIH
First posted: 2000-05-26
Sex: MALE
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: To examine clinical cardiovascular outcomes of African Americans.

Detailed description: BACKGROUND:

It has been well recognized for years that the survival rates among African-Americans with chronic diseases are reduced compared to their white counterparts. Recently attention has focussed on racial disparities in survival with chronic cardiovascular diseases. Prior to the widespread availability of coronary arteriography, African-Americans were thought to have a very low incidence of coronary artery disease. These findings appear to be inconsistent with the now generally accepted view that the coronary artery disease mortality rate is nearly equal in United States Black and white men and is increased in Black women as compared to white women.

Howard University and Howard University Hospital provided a unique environment for studying the clinical cardiovascular outcomes of African-Americans, in light of its history. That is, due to the influx of blacks into the District of Columbia in 1862, Freedmen's Hospital (which is now known as Howard University Hospital) was established for their care. Howard University Hospital has had an admissions profile with greater than 95 percent African-Americans for the past century

DESIGN NARRATIVE:

The study used previously collected data to: 1) examine the trends in mortality rates at Howard University Hospital, based on discharge status, between 1986 - 1992, for selected cardiovascular diseases; 2) compare cardiovascular mortality rate trends between Howard University Hospital and the National Hospital Discharge data; 3) examine cardiovascular co- morbidity experiences using a severity of illness index at Howard University Hospital compared to National data by race/ethnicity, geographic location and hospital bed size; and 4) identify a cohort of cardiovascular patients retrospectively based on repeated discharge data at Howard University Hospital, to analyze survival data.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility criteria: No eligibility criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05424029: Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
Official title: Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Non-Small Cell Lung Cancer
Keywords: Extracellular Vesicles and Particles
Biomarkers
22-155
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2022-06-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A member of the patient's treatment team, the protocol investigator, or the research team at MSK will identify potential research subjects

Brief summary: The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors contains enough vesicles to do testing that may help the researchers learn more about their NSCLC.


Eligibility criteria: Inclusion Criteria:

* All patients ≥ 18 years of age undergoing consideration of surgical resection, including lobar resections, sublobar resections, and pneumonectomies, for primary lung cancer will be eligible.
* Patients with previously resected disease and/or previous radiation therapy will be considered on a case by case basis.

Exclusion Criteria:

* Patients with active infection or pneumonia which may impact exosome makeup
* Additionally, if at the discretion of the operating surgeon, obtaining bronchial washings would lead to undue morbidity, the patient would be excluded and replaced

Primary outcomes:
measure: to isolate exosomes from bronchial washings
timeFrame: day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memorial Sloan Kettering Basking Ridge (Consent Only)
state: New Jersey
city: Middletown
country: United States
facility: Memorial Sloan Kettering Monmouth (Consent Only)
state: New Jersey
city: Montvale
country: United States
facility: Memorial Sloan Kettering Bergen (Consent Only)
state: New Jersey
city: Commack
country: United States
facility: Memorial Sloan Kettering Suffolk - Commack (Consent Only)
state: New York
city: Harrison
country: United States
facility: Memorial Sloan Kettering Westchester (Consent Only)
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Uniondale
country: United States
facility: Memorial Sloan Kettering Nassau (Consent Only)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: David Jones, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03997929: Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)
Official title: Prospective Evaluation of 1.3-ß-D-glucan in the Peritoneal Fluid for the Diagnosis of Fungal Peritonitis in Critically Ill Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intra Abdominal Infections
Candidiasis, Invasive
Peritoneal Candidiasis
Critically Ill
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2019-06-25
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Inclusion of 200 patients. Among them, identification of : 50 Cases (confirmed intra abdominal candidiasis) and 50 controls (intra abdominal infection without candida).

If more than 50 cases, random selection. Identification of control by matching (with confounding factors of the 1.3 BDG test). If more than 50 controls after matching, random selection.

Brief summary: New rapid diagnostic strategies are warranted in intra-abdominal candidiasis (IAC). A previous retrospective study showed that one measure, the day of the surgery, of peritoneal 1.3-Beta-D-Glucan ≤ 310pg/ml could rule out an IAC. This strategy was independent of the patient underlying conditions and Candida risk factors. This study aimed to confirm these results with a multicenter prospective study


Eligibility criteria: Inclusion Criteria:

* critically ill adult (\> 18 yrs old) admitted to ICU for intra-abdominal infection requiring surgery and possible intra abdominal candidiasis

Exclusion Criteria:

* declinate to participate,
* expected death within the first 24 hours

Primary outcomes:
measure: Measure of 1.3 BDG in the peritoneal exudate of patient with intra-abdominal candidiasis
timeFrame: 1 DAY
Secondary outcomes:
measure: Measure of 1.3 BDG in the serum of patient with intra-abdominal candidiasis
timeFrame: DAY 1 and DAY 3
Other outcomes:
Locations:
city: Metz
country: France
facility: CHR Mercy
state: Lorraine
city: Besançon
country: France
facility: PILI-FLOURY Sebastien
city: Dijon
country: France
facility: BOUHEMAD Belaid
city: Strasbourg
country: France
facility: POTTECHER Julien
Study officials:
affiliation: Central Hospital, Nancy, France
name: Emmanuel NOVY, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Novy, E.; Laithier, F.-X.; Riviere, J.; Remen, T.; Losser, M.-R.; Guerci, P.; Machouart, M. Protocol for the pBDG2 Study: Prospective Evaluation of 1.3-β-D-Glucan in the Peritoneal Fluid for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients. Microbiol. Res. 2021, 12, 196-203. https://doi.org/10.3390/microbiolres12010015
citation: Novy E, Laithier FX, Machouart MC, Albuisson E, Guerci P, Losser MR. Determination of 1,3-beta-D-glucan in the peritoneal fluid for the diagnosis of intra-abdominal candidiasis in critically ill patients: a pilot study. Minerva Anestesiol. 2018 Dec;84(12):1369-1376. doi: 10.23736/S0375-9393.18.12619-8. Epub 2018 Jul 9.
Clinical trial NCT00984529: Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
Official title: Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Heart Failure
Keywords: Chronic heart failure
candesartan cilexetil
clinical signs
symptoms
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-09-25
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary Care

Brief summary: The purpose of this study is to determine whether treatment with candesartan cilexetil for at least 6 months in patients with chronic heart failure improves clinical signs and symptoms of chronic heart failure.


Eligibility criteria: Inclusion Criteria:

* Patients with diagnosed chronic heart failure
* Patients treated for at least 6 months with candesartan cilexetil
* Signed Informed consent

Exclusion Criteria:

* Hypersensitivity to candesartan cilexetil
* Pregnancy / lactation
* Severe hepatic impairment

Primary outcomes:
measure: To evaluate clinical signs and symptoms of chronic heart failure (in terms of NYHA status, fluid retention and tiredness/fatigue) after at least 6 months of treatment with candesartan cilexetil
timeFrame: 1 visit (after at least 6 months of treatment)
Secondary outcomes:
measure: To evaluate ventricular function after at least 6 months of treatment with candesartan cilexetil
timeFrame: 1 visit (after at least 6 months of treatment)
measure: To gain insight into usage of candesartan cilexetil in real life for chronic heart failure in Croatia
timeFrame: 1 visit (after at least 6 months of treatment)
measure: To evaluate patient's compliance with prescribed treatment
timeFrame: 1 visit (after at least 6 months of treatment)
Other outcomes:
Locations:
city: Biograd
country: Croatia
facility: Research Site
city: Bjelovar
country: Croatia
facility: Research Site
city: Cakovec
country: Croatia
facility: Reserach Site
city: Karlovac
country: Croatia
facility: Research Site
city: Krapinske Toplice
country: Croatia
facility: Reserach Site
city: Novi Marof
country: Croatia
facility: Research Site
city: Opatija
country: Croatia
facility: Research Site
city: Osijek
country: Croatia
facility: Research Site
city: Pula
country: Croatia
facility: Research Site
city: Rijeka
country: Croatia
facility: Research Site
city: Sl. Brod
country: Croatia
facility: Reserach Site
city: Split
country: Croatia
facility: Research Site
city: Stubicke Toplice
country: Croatia
facility: Research Site
city: Zabok
country: Croatia
facility: Reserach Site
city: Zagreb
country: Croatia
facility: Research Site
Study officials:
References:
Clinical trial NCT03103529: Safety and Feasibility of Early Active Rehabilitation in Children After Concussion
Official title: Safety and Feasibility of Early Active Rehabilitation in Children After Concussion
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Post-Concussion Symptoms
Concussion
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
First posted: 2017-04-06
Enrollment: 20
Sex: ALL
Minimum age (years): 8
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It has been suggested that activity immediately following concussion is detrimental to recovery and may lead to long term impairments. The animal model has shown that exercise too soon can lead to neurometabolic energy imbalances within the brain. However, there is also evidence to suggest that prolonged inactivity has negative consequences that may contribute to prolongation of symptoms. Determining the ideal timeframe in which to initiate an active rehabilitation protocol for patients who are slow to recovery is an important factor in concussion management.


Eligibility criteria: Inclusion Criteria:

* referred to the mTBI clinic of the MCH for atypical recovery (defined as the presence of symptoms with little improvement at 10 days post-injury preventing them from entering standard return to activities protocols)

Exclusion Criteria:

* co-morbidity preventing children from participating in intervention

Primary outcomes:
measure: Post-concussion symptoms
timeFrame: 6 weeks post-injury
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Montreal Children's Hospital, MUHC
state: Quebec
Study officials:
References:
Clinical trial NCT00658229: The Physical Exercise and Prostate Cancer Study
Official title: Physical Exercise for Patients With Prostate Cancer During Androgen Deprivation Therapy - A Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Prostate Cancer
Keywords: Exercise
Prostatic
Neoplasm
Androgen
Deprivation
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: Ullevaal University Hospital
name: Norwegian School of Sport Sciences
name: University of Alberta
name: University of Oslo
name: Norwegian Foundation for Health and Rehabilitation
name: The Royal Norwegian Ministry of Health
First posted: 2008-04-14
Enrollment: 60
Sex: MALE
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine the effectiveness of a four months strength training program on physical and psychological health in patients with prostate cancer during androgen deprivation therapy. It is hypothesized a beneficial effect of the intervention on physical and psychological health in patients with prostate cancer treated with androgen deprivation.


Eligibility criteria: Inclusion Criteria:

* Newly diagnosed locally advanced prostate cancer (clinical stage T2 and T3)
* Referred to RH and UUS for radiotherapy
* \< 75 years
* Capable of reading and writing Norwegian
* Treating oncologist must approve of the subjects' participation
* Living within approximately 1 hour from Oslo by car or public transportation

Exclusion Criteria:

* Routinely resistance training with manuals
* Medication for osteoporosis (i.e. bisphosphonates)
* Conditions of a severity that contraindicate exercise without adjusted actions
* Mentally incompetent conditions
* Conditions of a severity that complicates the ability to participate in a supervised training program

Primary outcomes:
measure: lean body mass
timeFrame: before ADT, before and after the intervention
Secondary outcomes:
measure: bone mineral density, fat mass, body mass index, serological outcomes (including lipids, hormones and CRP), physical functioning, psycho-social functioning and muscle cellular outcomes (including muscle fiber size and function)
timeFrame: before ADT, before and after the intervention
Other outcomes:
Locations:
city: Montebello
country: Norway
facility: Rikshospitalet- Radiumhospitalet HF
state: Oslo
Study officials:
affiliation: Oslo University Hospital
name: Lene Thorsen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Thorsen L, Nilsen TS, Raastad T, Courneya KS, Skovlund E, Fossa SD. A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design. BMC Cancer. 2012 Mar 29;12:123. doi: 10.1186/1471-2407-12-123.